• Criptovalute
  • Mercati Predittivi
  • Notizie
  • Trading Agentico
  • Articoli
  • Leghe

Cerca Criptovalute

Criptovalute di tendenza

CoinRithm

Azienda

Entità legale
Bees-x Limited
Numero società
13308136
Costituita in
England and Wales
Sede legale
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm è un servizio di informazione e ricerca gestito da Bees-x Limited. Non è autorizzato dalla Financial Conduct Authority (FCA) a svolgere attività regolamentate e nulla su questo sito costituisce consulenza finanziaria.

Esplora

CriptovaluteMercati PredittiviNotizieArticoliAgent ArenaLeghe

Funzionalità

CruscottoScambio DimostrativoTrading AgenticoPortafoglioLista di ControlloImpostazioni

Azienda

Chi SiamoMetodologiaTermini di UsoPolitica sulla RiservatezzaPolitica sui CookieDisconoscimento

Assistenza

Supporto ClientiDomande FrequentiKit per sviluppatoriDocumentazione MCP

Social

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Tutti i diritti riservati.
Disponibile su Google PlayScarica su App Store
  • Home
  • MercatiMercati Predittivi
  • Notizie
  • Cruscotto
  1. Mercati Predittivi
  2. Health & Medicine
  3. FDA approves Ionis' Olezarsen?
FDA approves Ionis' Olezarsen?

FDA approves Ionis' Olezarsen?

Health & MedicineOne-Off18g
PolymarketPolymarketVerifica disponibilitàSenza KYC2% di commissione
Probabilità implicita attuale
Sì
Sì 88%
Qualita del mercato

44 / 100

Bassa qualità
Volume 24h

1 €

Liquidità

1,7K €

Bassa liquidità
Bid / Ask

86.0% / 90.0%

Spread

4.7%

Spread moderato
Dati di mercato

Aggiornato 4 minuti fa

4 giu 26, 20:0430 giu 26, 0:00

Trend

Esito24hProbabilità

Esito scelto

Yes88%

Regole

As of market creation, the FDA's expected decision date for the specified application is June 30, 2026.

Polymarket
  • This market will resolve to "Yes" if the U.S.
  • Food and Drug Administration (FDA) grants full or conditional approval for Ionis's Olezarsen as a treatment for severe hypertriglyceridemia by July 14, 2026, 11:59 PM ET.
  • Otherwise, this market will resolve to "No."
  • An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
  • The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

Mercati Correlati

Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

145,3K €
Sì: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

16,6K €
Sì: 10%PolymarketPOLYMARKET
Ebola pandemic in 2026?

Ebola pandemic in 2026?

8,7K €
Sì: 8%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

1,3K €
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Which disease will be eradicated next in humans?

462,5 €
Polio: 26.7%Manifold MarketsMANIFOLD MARKETS
When, where or how will Trump die?

When, where or how will Trump die?

137,8 €
2025: 0%Manifold MarketsMANIFOLD MARKETS

Attivi in questi argomenti

BitcoinBTC$62,971.45+2.51%EthereumETH$1,660.91+1.76%SolanaSOL$65.40+1.71%DogecoinDOGE$0.0851+1.56%XRPXRP$1.12+0.44%BNBBNB$597.13+1.82%

Notizie Correlate

Chainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.NewsBrian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto News

Regole

As of market creation, the FDA's expected decision date for the specified application is June 30, 2026.

Polymarket
  • This market will resolve to "Yes" if the U.S.
  • Food and Drug Administration (FDA) grants full or conditional approval for Ionis's Olezarsen as a treatment for severe hypertriglyceridemia by July 14, 2026, 11:59 PM ET.
  • Otherwise, this market will resolve to "No."
  • An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
  • The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs